ATA Guidelines Tools

Recurrent / Persistent Nodal Disease

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link:

Contents of this Issue


Page 3 of 3

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 For additional copies, order at Copyright © 2015 All rights reserved ATAREC15082 Disclaimer is Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Abbreviations DTC, differentiated thyroid cancer; RLN, recurrent laryngeal nerve; FDG, 18F-Fluorodeoxyglucose; PET, positron emission tomography Source Tufano RP, Clayman G, Heller KS, et al. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. yroid, a Mary Ann Liebert, Inc. publication. 2015;25(1):15-27. American yroid Association, Inc. 6066 Leesburg Pike, Suite 550 • Falls Church, Virginia 22041 Phone: 703.998.8890 • Fax: 703.998.8893 • Physician referral, patient resources available online in English and Spanish.

Articles in this issue

Links on this page

Archives of this issue

view archives of ATA Guidelines Tools - Recurrent / Persistent Nodal Disease